CaMKII as a Therapeutic Target in Cardiovascular Disease
Oscar E. Reyes Gaido, Lubika J. Nkashama, Kate L. Schole, Qinchuan Wang, Priya Umapathi, Olurotimi Mesubi, Klitos Konstantinidis, Elizabeth D. Luczak, Mark E. Anderson
Abstract
and calmodulin-dependent protein kinase II) is a highly validated signal for promoting a variety of common diseases, particularly in the cardiovascular system. Despite substantial amounts of convincing preclinical data, CaMKII inhibitors have yet to emerge in clinical practice. Therapeutic inhibition is challenged by the diversity of CaMKII isoforms and splice variants and by physiological CaMKII activity that contributes to learning and memory. Thus, uncoupling the harmful and beneficial aspects of CaMKII will be paramount to developing effective therapies. In the last decade, several targeting strategies have emerged, including small molecules, peptides, and nucleotides, which hold promise in discriminating pathological from physiological CaMKII activity. Here we review the cellular and molecular biology of CaMKII, discuss its role in physiological and pathological signaling, and consider new findings and approaches for developing CaMKII therapeutics.